Published October 2019
| Version v1
Journal article
Meeting report of the 7th Heidelberg Myeloma Workshop: today and tomorrow
- 1. University Hospital Heidelberg, Hematology, Oncology and Rheumatology (Germany)
Description
Purpose
The 7th Heidelberg Myeloma Workshop was held on April 5th and 6th, 2019 at the University Hospital Heidelberg.Methods and results
Main topics of the meeting were (1) diagnostics and prognostic factors, (2) role of immunotherapy in multiple myeloma (MM), (3) current therapy of MM, (4) biology and genomics of MM as well as (5) novel treatment concepts. A debate on the status of minimal residual disease (MRD) driven therapy was held.
Conclusion
Diagnostics and treatment of newly diagnosed and relapsed MM are continuously evolving. While advances in the field of (single cell) genetic analysis now allow for characterization of the disease at an unprecedented resolution, immunotherapeutic approaches and MRD testing are at the forefront of the current clinical trial landscape.
Additional details
Identifiers
Publishing Information
- Journal Title
- Journal of Cancer Research and Clinical Oncology
- Journal Volume
- 145
- Journal Issue
- 10
- Journal Page Range
- p. 2445-2455
- ISSN
- 0171-5216
- CODEN
- JCROD7
INIS
- Country of Publication
- Germany
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 54092125
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- CLINICAL TRIALS; DIAGNOSIS; GENETICS; HOSPITALS; IMMUNOTHERAPY; NEOPLASMS
- Descriptors DEC
- BIOLOGY; BUILDINGS; DISEASES; MEDICAL ESTABLISHMENTS; MEDICINE; TESTING; THERAPY
Optional Information
- Copyright
- Copyright (c) 2019 Springer-Verlag GmbH Germany, part of Springer Nature